FindTrial
Sign In

Effect of sarcubitril valsartan in antihypertension and improvement of prognosis of cardiovascular diseases in patients on hemodialysis

A cohort study on the effect of sarcubitril valsartan in antihypertension and improvement of prognosis of cardiovascular diseases in patients on hemodialysis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064406
Enrollment
Unknown
Registered
2022-10-06
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

case series:sarcubitril valsartan

Sponsors

Department of Nephrology Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Dialysis age >=6 months; 3. The blood pressure reached the standard within the past 1 week, that is, SBP =3 times/week, and >=10 hours/week; 5. Patients who have not used sakubactriovalsartan in the past.

Exclusion criteria

Exclusion criteria: 1. Angioedema in the past; 2. Severe sleep disorder; 3. Severe cognitive impairment or Alzheimer's disease; 4. Within 1 month after myocardial infarction; Within 3 months after a hemorrhage or ischemic stroke.

Design outcomes

Primary

MeasureTime frame
echocardiogram;—

Countries

China

Contacts

Public ContactChen Yuqing

Peking University First Hospital

cyq@bjmu.edu.cn+86 15901285602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026